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Abstract
Purpose—This phase I study investigated the safety, dose limiting toxicity, and efficacy in three 
cohorts all treated with the mTOR inhibitor everolimus that was delivered 1) in combination with 
5-fluourouracil with leucovorin (5-FU/LV), 2) with mFOLFOX6 (5-FU/LV + Oxaliplatin), and 3) 
with mFOLFOX6 + panitumumab in patients with refractory solid tumors.
Methods—Patients were accrued using a 3-patient cohort design consisting of two sub-trials in 
which the maximum tolerated combination (MTC) and dose-limiting toxicity (DLT) of everolimus 
and 5-FU/LV was established in sub-trial A and of everolimus in combination with mFOLFOX6 
and mFOLFOX6 plus panitumumab in sub-trial B.
Results—Thirty six patients were evaluable for toxicity, 21 on Sub-trial A and 15 on Sub-trial B. 
In Sub-trial A, DLT was observed in 1/6 patients enrolled on dose level 1A and 2/3 patients in 
Level 6A. In sub-trial B, 2/3 patients experienced DLT on Level 1B and subsequent patients were 
enrolled on Level 1B-1 without DLT. 3/6 patients in cohort 2B-1 experienced Grade 3 mucositis 
and further study of the combination of everolimus, mFOLFOX6, and panitumumab was aborted. 
Among the 24 patients enrolled with refractory metastatic colorectal cancer, the median time on 
treatment was 2.7 months with 45% of patients remaining on treatment with stable disease for at 
least three months.
Conclusions—While a regimen of everolimus in addition to 5-FU/LV and mFOLFOX6 appears 
safe and tolerable, the further addition of panitumumab resulted in an unacceptable level of 
toxicity that cannot be recommended for further study. Further investigation is warranted to better 
elucidate the role in which mTOR inhibitors play in patients with refractory solid tumors, with a 
specific focus on mCRC as a potential for the combination of this targeted and cytotoxic therapy 
in future studies.
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Colorectal cancer remains the third most common cause of cancer diagnosed in the United 
States with an estimated 50,000 deaths in 20121. Approximately one fourth of patients will 
present with metastatic disease at the time of diagnosis with average life expectancies of 
about two years. The backbone of treatment for patients with metastatic colorectal cancer 
(mCRC) remains 5-fluorouracil (5-FU), a nucleoside analog that when infused with 
oxaliplatin (mFOLFOX6), results in median survival rates of approximately 18 to 20 
months. More recently, the repertoire of agents approved to treat mCRC has expanded to 
include targeted agents that take advantage of key signal transduction pathways involved in 
colon cancer tumorigenesis. Notable among these is the EGFR pathway, which in tumors 
expressing wild-type KRAS proteins, can be inhibited with antibodies that target the 
receptor-ligand interaction. EGFR activation results in activation of KRAS, a downstream 
target of which is the phosphatidylinositide 3-kiase (PI3K) pathway. The PI3K pathway 
plays a key role in cell growth and survival mediated at least in part via activation of 
mammalian target of rapamycin (mTOR), an intracellular protein kinase implicated in cell 
cycle control2.
Everolimus (RAD001) is a novel macrolide derivative of rapamycin that acts by selectively 
inhibiting mTOR. It is currently approved for the treatment of metastatic renal cell 
carcinomas and pancreatic neuroendocrine tumors3. In vitro studies of everolimus 
demonstrate inhibition of the proliferation of numerous solid tumor cell lines, including 
CRC cell lines harboring mutations in KRAS and PIK3CA, the latter of which encodes the 
active subunit of PI3K and is altered in 10-30% of CRC tumors4. Everolimus has also been 
shown to inhibit growth of CRC tumor xenografts in vivo both as a single agent and in 
combination with chemotherapeutics and additional targeted agents5,6.
Studies of single agent everolimus in refractory solid tumors have not produced a strong 
signal for activity in colorectal cancer7. Three phase II trials have targeted the drug 
specifically for refractory CRC with the majority of patients achieving stable disease but 
with disappointing objective response rates8-10. Pre-clinical data in colorectal cancer cell 
lines and xenografts suggests that mTOR inhibition alone results in increased activation of 
EGFR and only transient inhibition of the PI3K pathway11. Subsequent co-treatment with 
the EGFR inhibitor erlotinib has demonstrated more prolonged suppression of the mTOR 
pathway and resulted in tumor shrinkage. Temsirolimus, an IV administered rapalogue of 
everolimus, has also been shown to decrease resistance to cetuximab in colon cancer cell 
lines12.
With these combinations, however, comes the risk of overlapping toxicity that may limit the 
dose of everolimus used. An earlier trial of temsirolimus combined with infusional 5-FU in 
patients with refractory solid tumors reported mucositis as a significant dose-limiting 
toxicity resulting in two deaths from bowel perforation13. Given these concerns, balanced 
with the potential benefit of inhibiting the PI3K/AKT/mTOR pathway, we proposed a study 
investigating the feasibility of everolimus in combination with commonly used 
chemotherapy backbones for the treatment of mCRC. We developed a Phase I trial to 
determine the dose-limiting toxicities (DLTs) and maximum tolerated combinations (MTC) 
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of everolimus when combined with 5-FU/LV, mFOLFOX6, and mFOLFOX6 plus 
panitumumab in patients with refractory solid tumors.
METHODS
Patient Eligibility
Eligible patients for this study had histologically confirmed metastatic solid malignancies 
with no clearly effective standard therapeutic options available based either on prior therapy 
or disease type. Patients with tumor histologies potentially sensitive to EGFR-targeted 
therapy were recruited preferentially. The study was amended to restrict enrollment of 
patients with mCRC receiving panitumumab to those with KRAS wild-type tumors after 
data by Amado et al. was published that reported a requirement of KRAS wild-type status 
for panitumumab efficacy14. Other inclusion criteria included: age ≥ 18 years; Eastern 
Cooperative Oncology Group (ECOG) performance status of 0-2; evaluable disease by 
Response Evaluation Criteria in Solid Tumors (RECIST); and a minimum of three weeks 
since major surgery, completion of radiation or completion of all prior systemic anticancer 
therapy. Patients were required to have adequate organ function, including an absolute 
neutrophil count (ANC) ≥ 1500 cells/mm3, a platelet count ≥ 100,000/mm3, a creatinine 
clearance ≥ 60ml/min as calculated by the Cockcroft-Gault formula, a total bilirubin ≤ 1.2 
mg/dL, transaminases ≤ 2.5 × ULN (or ≤ 5 × ULN if in cases of known liver metastases or 
primary liver cancer), and a magnesium greater than or equal to the lower limits of normal. 
Patients enrolled on study were required to discontinue all medications that are known 
inducers or inhibitors of cytochrome P450 3A4 (CYP3A4). Additional exclusion criteria 
included the presence of grade 2 or greater neuropathy at the time of study entry; pregnancy, 
breastfeeding or unwilling to use contraception; impairment of gastrointestinal function 
leading to altered absorption; active bleeding; and any concurrent life-threatening acute 
medical problem at the discretion of the investigator.
This study received approval by the Institutional Review Board (IRB) of the University of 
North Carolina at Chapel Hill. This trial was registered with United States National 
Institutes of Health (trial number: NCT00610948). Written informed consent was obtained 
from all participants prior to any study-related procedures or treatment.
Study Design
The primary objective of this study was to determine the MTC of everolimus in combination 
with each of the following: 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab. 
Secondary objectives included determining the adverse event profile of the above 
combinations and evaluating preliminary evidence of anti-tumor activity using RECIST 
criteria. Toxicity was graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0. Any grade 3 or 4 non-
hematologic toxicity that occurred during the first cycle of treatment (28 days) was 
considered a DLT with the exception of grade 3 skin rash, or grade 3 nausea/grade 3 
diarrhea that could be controlled within one week. An ANC of less than 500 cells/mm3 
lasting more than seven days or associated with fever or infection OR a platelet count of less 
than 25,000/mm3 with major bleeding was considered dose limiting. No intra-patient dose 
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escalation was permitted. Any patient who received at least one day of treatment with 
everolimus was evaluable for toxicity provided they were not replaced. Patients who 
received therapy for at least one cycle (28 days) or whose treatment was discontinued due to 
DLT were evaluable for DLT.
This study was conducted serially in two parts: 1) Sub-trial A consisting of everolimus plus 
5-FU/LV followed by 2) Sub-trial B consisting of everolimus plus mFOLFOX6 followed by 
everolimus plus mFOLFOX6 and panitumumab. A separate, parallel trial was conducted 
with the combination of everolimus and panitumumab. That trial will be reported separately; 
however, it did help inform the dose escalation of the current trial. Patients in Sub-trial A 
were treated with 5-FU/LV that was given on Days 1 and 15 of each cycle as a bolus of 5-
FU given after LV, followed by a 46 hour infusion of 5-FU via ambulatory pump. 
Everolimus was initially administered as a weekly oral dose but the study was subsequently 
amended to daily dosing. Enrollment onto Sub-trial B commenced at one dose lower than 
the MTC of everolimus and 5-FU/LV as determined in Sub-trial A based on toxicity 
observed in a prior study of temsirolimus and 5-FU. To start a new treatment of FOLFOX 
on Day 15 or to initiate a new cycle of therapy, patients were required to- have an absolute 
neutrophil count (ANC) of ≥ 1000 cells/mm3, platelets ≥ 100,000/mm3 with all toxicities 
resolved to grade 1 or to entry criteria.
Both sub-trials utilized a standard “3+3” trial design. The dose escalation schema is 
represented in Table 1. If no DLT was observed at the initial dose level after 3 patients 
completed one cycle of therapy, accrual to the subsequent dose level was permitted. If 1/3 
patients in any one dose level experienced DLT, then that cohort was expanded to 6 patients. 
If a minimum of 2/6 patients in the expanded cohort experienced DLT, the MTC was 
deemed to be exceeded and the estimated MTC was defined as one dose level lower. If the 
MTC was surpassed in the first dose level cohort, a dose cohort minus one was utilized.
Baseline assessments prior to treatment consisted of a medical history and physical exam, an 
assessment of ECOG performance status, chest x-ray, baseline laboratory measurements and 
an imaging study of evaluable disease. Treatment assessments, including symptom directed 
history and physical exam as well as toxicity assessments, were required on a weekly basis 
during the first four weeks of therapy, then on the first day of each 28 day cycle thereafter. 
Tumor response was assessed according to RECIST criteria every two cycles (8 weeks) with 
imaging modalities deemed appropriate by the investigator.
RESULTS
Patient Characteristics
A total of thirty nine patients were treated at a single institution on study from March 2008 
until March 2013, with 21 patients enrolled on Sub-trial A and 18 patients on Sub-trial B. 
Three patients were replaced and hence not evaluable for DLT due to their discontinuation 
of treatment prior to completing cycle one without DLT (reasons being patient preference, 
oxaliplatin infusion reaction on day 1 of treatment and insurance denial). The remaining 
thirty six received everolimus in combination with 5-FU/LV, mFOLFOX6 or mFOLFOX6 
plus panitumumab for at least one cycle (28 days) unless discontinued for DLT and were 
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evaluable for toxicity (Table 2). The median age of all patients enrolled was 57 years (range 
35-77). Overall, 24 women and 14 men were treated on study. The majority of patients 
enrolled on both arms were Caucasian with a higher proportion of African-Americans 
enrolled on Sub-trial B (25% versus 0%). Twenty four (67%) patients enrolled had mCRC. 
Patients had received a median of two prior therapies.
DLT and determination of MTC
DLT associated with everolimus and chemotherapy is summarized in Table 3. Patients were 
required to keep a pill diary of their everolimus administration; no issues with compliance 
were documented. In Sub-trial A, DLT (angioedema) was observed in one of three patients 
enrolled on dose Level 1A. The remaining two patients remained on study for 1 and 6 
cycles, respectively. Three additional patients for a total of six were enrolled on this cohort 
with no additional DLT observed. One patient in cohort 1A experienced a dose delay during 
cycle 5 secondary to an upper respiratory infection not related to treatment. Subsequent 
cohorts 2A, 3A, 4A, and 5A were completed without DLT. Two out of three patients in 
cohort 2A had dose delays or reductions for neutropenia and elevated liver enzymes (in 
cycles 2 and 3, respectively). One patient in cohort 3A experienced a two week delay of 5-
FU and everolimus in cycle 5 for diarrhea and mucositis. All three patients in cohort 4A had 
dose reductions (in cycles 2, 3 and 4) for non-dose limiting toxicity, namely mucositis and 
hyponatremia. Two of three patients experienced DLT in Level 6A, consisting of grade 3 
hypophosphatemia, grade 3 hypokalemia and grade 3 hyperglycemia. Therefore, the MTC 
of Sub-trial A was determined to be 5mg of everolimus and 5-FU bolus of 400mg/m2 
followed by 5-FU infusion of 2400mg/m2. Patients subsequently enrolling on Sub-trial B 
were initiated on one dose cohort lower (5mg of everolimus and 5-FU bolus of 400mg/m2 
followed by 5-FU infusion of 1800mg).
Within Sub-trial B, one of three patients enrolled on Level 1B experienced DLT, specifically 
grade 3 hypophosphatemia and grade 3 fatigue. The other two patients experienced dose 
delays in cycles 3 and 5 for neutropenia, thrombocytopenia, fatigue and mucositis. An 
expansion of three additional patients was planned to this cohort; however, the first patient 
enrolled in the expansion cohort experienced DLT of grade 3 mucositis and grade 3 
dehydration. Thus, subsequent patients were enrolled on Level 1B-1 with an oxaliplatin dose 
of 65mg/m2. All five patients enrolled at this dose level received treatment without DLT. 
Two patients in this cohort reported non-dose limiting toxicity (thrombocytopenia and 
neutropenia) in cycle 2 that required dose delays or reductions. The final cohort 2B-1 was 
then initiated with the addition of panitumumab to everolimus and mFOLFOX6. One of 
three patients in this cohort experienced DLT of grade 3 mucositis. Therefore, the cohort 
was expanded to six patients. In total, three out of the six patients in cohort 2B-1 
experienced grade 3 mucositis. Other adverse events that required dose delays or reductions 
in this cohort occurred in five out of six patients and included neutropenia, 
thrombocytopenia, rash, pneumonitis, neuropathy, fatigue, and hypokalemia. Therefore, 
further study of the combination of everolimus, mFOLFOX6 and panitumumab was aborted 
due to excessive toxicity in spite of reduced doses of all agents.
McRee et al. Page 5














All patients enrolled on study reported at least one treatment-related adverse event with 33% 
of patients in Sub-trial A and 80% in Sub-trial B reporting at least one grade ≥ 3 adverse 
event (Tables 4 and 5). The most commonly reported treatment-related toxicity overall in 
both groups was mucositis. For intolerable grade 2 mucositis, everolimus was held until 
recovery to ≤ grade 1 with re-introduction at the same dose. If grade 2 toxicity recurred, the 
everolimus dose was reduced. For grade 3 and 4 mucositis, everolimus was held until 
recovery to entry criteria after which it was restarted at the next lowest dose level and a dose 
reduction occurred.
In Sub-trial A, other common treatment-related toxicities (all grades) included 
hypercholesterolemia (62%), fatigue (52%), anemia (52%), leukopenia (48%), nausea (38%) 
and neutropenia (38%). A total of 12 grade ≥ 3 treatment-related AEs were reported, 
including mucositis (n=3), hypophosphatemia (n=2), fatigue (n=1), neutropenia (n=1), 
thrombocytopenia (n=1), anorexia (n=1), diarrhea (n=1), hyperglycemia (n=1), hypokalemia 
(n=1) and angioedema (n=1).
In Sub-trial B, a total of 47 AEs were reported amongst 15 patients. Across all arms, the 
most common treatment related AEs (all grades) were mucositis (67%), neutropenia (53%), 
fatigue (53%), diarrhea (47%), anemia (47%) and thrombocytopenia (47%). Within Arm 1B, 
thirteen treatment related grade ≥ 3 AEs were reported, including dehydration, diarrhea, 
fatigue, anemia, mucositis, neutropenia, thrombocytopenia and hypokalemia. In Arm 1B-1, 
only four treatment related grade ≥ 3 AEs were reported, specifically diarrhea, neutropenia, 
thrombocytopenia and an oxaliplatin-related infusion reaction. Eight treatment related grade 
≥ 3 AEs were reported in Arm 2B-1 and included diarrhea, anemia, mucositis, neutropenia 
and thrombocytopenia. Only two incidents of acneiform rash were reported among the six 
patients who received panitumumab, both of which were graded ≤ 3 in severity.
Clinical benefit
Of the 36 patients evaluated for toxicity on trial, 32 were evaluable for response. Four 
patients were not evaluable given that they discontinued therapy due to toxicity prior to two 
cycles of treatment being completed. The median number of cycles received by all evaluable 
patients was three (range 1-19 in Sub-trial A, range 1-7 in Sub-trial B). Thirteen patients 
experienced progressive disease at initial evaluation. In Sub-trial B, two patients (diagnosed 
with cholangiocarcinoma and esophageal adenocarcinoma) had unconfirmed partial 
responses (PR) and remained on trial for three and seven cycles, respectively. Both of these 
patients received treatment with everolimus, mFOLFOX6 and panitumumab. Seventeen 
patients (53%) achieved a best response of stable disease with 13 of those patients 
maintaining stable disease for ≥ 3 months. Among the 24 patients enrolled with mCRC, the 
median time on treatment was 2.69 months with 11 patients (45%) remaining on treatment 
with stable disease for at least three months (Figure 1). Two refractory mCRC patients in 
Sub-trial A remained on treatment for 21.84 and 10.31 months, respectively, with stable 
disease.
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This phase I study was conducted to determine the DLT and MTC of everolimus when 
combined with 5-FU/LV, mFOLFOX6, and mFOLFOX6 plus panitumumab in patients with 
refractory solid tumors. It was comprised of two sub-trials that utilized the MTC of 
everolimus with 5-FU/LV to further evaluate the safety profile of everolimus in combination 
with doublet chemotherapeutics and an EGFR inhibitor. While a regimen of everolimus in 
addition to 5-FU/LV and mFOLFOX6 appears safe and tolerable, the further addition of 
panitumumab resulted in an unacceptable level of toxicity and that combination cannot be 
recommended for further study.
In reviewing Sub-trial A, in which patients received increasing doses of everolimus 
combined with 5-FU/LV, the MTC was determined to be 5mg of daily everolimus combined 
with standard doses of bolus 5-FU followed LV and a 46 hour 5-FU infusion (400mg/m2 
and 2400mg/m2 respectively). Dose limiting toxicities in these patients were primarily 
metabolic, consisting of hyperglycemia, hypophosphatemia and hypokalemia. Treatment 
with mTOR inhibitors results in a rise in glucose levels via down-regulation of mRNA 
translation of glucose transporters, specifically GLUT-515. Similarly, low phosphate levels 
are a well-documented side effect of mTOR inhibitors, and while the mechanism is less well 
understood, can result in skeletal muscle weakness due to depletion of adenosine 
triphosphate (ATP) if phosphate levels are not properly repleted. The most commonly 
occurring DLT in Sub-trial B was mucositis. While approximately 80% of patients in Sub-
trial A reported any degree of mucositis, only 3 patients developed ≥ grade 3 mucositis. 
Alternatively, in Sub-trial B, mucositis was reported in 10 out of the 15 patients treated, 
30% of who reported ≥ grade 3 mucositis, mostly in those treated with panitumumab. While 
stomatitis is reportedly a rarer side effect of anti-EGFR antibodies, the possibility of a 
synergistic effect of everolimus, 5-FU/LV and panitumumab on the mucosa resulting in 
overlapping toxicity must be considered.
We found the MTC of everolimus to be 5mg daily in combination with 5-FU/LV 
(400mg/m2/2400mg/m2) and oxaliplatin (65mg/m2) administered every two weeks. Overall, 
there were no treatment related dose delays or reductions during the first cycle of therapy in 
all cohorts except 2B-1, which included panitumumab. The addition of panitumumab, even 
at lower than standard doses of 3.6mg/kg, was not tolerated due to dose limiting mucositis. 
In our parallel study of everolimus and panitumumab that will be reported separately, 
mucositis proved dose limiting leading to an inability to escalate to standardly tolerated 
doses of each drug when administered as a single agent. For patients with refractory mCRC, 
however, the combination of 5-FU- based chemotherapy with PI3K inhibition appears to be 
safe and well tolerated. Median overall survival (OS) for all evaluable patients enrolled on 
trial with mCRC was 5.9 months, with patients on sub-trial A exhibiting a median OS of 6.9 
months. These outcomes are similar to those reported for refractory mCRC patients treated 
with regorafenib, an oral multi-tyrosine kinase inhibitor, which when compared to placebo 
resulted in an OS of 6.4 months16. Thus, further investigation is warranted to better 
elucidate the role in which mTOR inhibitors play in patients with refractory solid tumors, 
with a specific focus on mCRC as a potential target tumor type for this combination in 
future studies.
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Time on treatment for all mCRC patients.
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Table 1
Dose Escalation Scheme
Sub-Trial A Levels Everolimus Dose (mg) 5-FU Dose (B/I in mg/m2)
a LV Dose (mg/m2)
1A 15 (weekly) 400/1800 400
2A 30 (weekly) 400/1800 400
3A 2.5 (daily) 400/1800 400
4A 5 (daily) 400/1800 400
5A 5 (daily) 400/2400 400
6A 10 (daily) 400/2400 400





LV Dose (mg/m2) Oxaliplatin Dose (mg/m2) Panitumumab Dose (mg/kg)
1B
A-1 level
b A-1 level 400 85 0
1B-1 A-1 level A-1 level 400 65 0
2B-1 A-1 level A-1 level 400 65 3.6
a
B/I = Bolus/Infusion dose (Infusion occurs over 46 hours)
b
Dose as determined in Sub-trial A (A-1 = one dose level below MTC in Sub-trial A)
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Table 2
Patient Characteristics
Characteristics Sub-trial A Sub-trial B
Total Number of Patients 21 15
Median Age (years) 58 (range 35- 77) 57 (range 38 – 73)
Gender
    Male 8 6
    Female 13 9
Race
    White 20 10
    Black 0 4
    Asian 1 1
Median Number of Previous Therapies 2 (range 1-5) 2 (range 1-4)
Tumor Type
    Colorectal 17 7
        KRAS Wild-type 2 7
        KRAS Mutant 11 0
        Unknown 4 0
    Esophagogastric 1 2
    Pancreas 2 1
    Appendiceal Adenocarcinoma 1 0
    Small bowel Adenocarcinoma 0 1
    Cholangiocarcinoma 0 3
    Adrenal Cortical Carcinoma 0 1
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Table 3
Dose Limiting Toxicities
Dose Level # Treated Patients # Patients with DLT
Level 1A
RAD001 15mg weekly










































5FU (B/I) 400/1800 mg/m2
Oxaliplatin 65 mg/m2
Panitumumab 3 6 mg/kg
6 3
- Mucositis
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Table 4
Most frequent adverse events in Sub-trial A
N = 21
Adverse Event All grades (%) Grade ≥ 3
Mucositis 17 (81) 3
Hypercholesteremia 13 (62) 0
Fatigue 11 (52) 1
Anemia 11 (52) 0
Leukopenia 10 (48) 0
Nausea 8 (38) 0
Neutropenia 8 (38) 1
Thrombocytopenia 7 (33) 1
Anorexia 7 (33) 1
Hypertriglyceridemia 6 (29) 0
Diarrhea 5 (24) 1
Hyperglycemia 4 (19) 1
Transaminitis 4 (19) 0
Abdominal pain 4 (19) 0
Hypophosphatemia 4 (19) 2
Hypokalemia 4 (19) 1
Rash/desquamation 4 (19) 0
Vomiting 4 (19) 0
Constipation 3 (14) 0
Fever 3 (14) 0
Epistaxis 3 (14) 0
Hypomagnesemia 3 (14) 0
Weight loss 3 (14) 0
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Table 5
Most frequent adverse events for sub-trial B
Adverse Event (All grades) Arm 1B (N=4) Arm 1B-1 (N=5) Arm 2B-1 (N=6) Total percentage (N = 15)
Mucositis 3 2 5 67
Neutropenia 4 2 2 53
Fatigue 3 2 3 53
Diarrhea 3 3 1 47
Anemia 3 2 2 47
Thrombocytopenia 4 1 2 47
Nausea 2 3 1 40
Hypokalemia 2 1 3 40
Anorexia 3 1 1 33
Rash/desquamation 0 1 3 27
Leukopenia 4 0 0 27
Hypertriglyceridemia 3 0 0 20
Sensory neuropathy 2 0 1 20
Vomiting 2 1 0 20
Transaminitis 1 2 0 20
Hypocalcemia 2 0 1 20
Hypomagnesemia 1 1 0 13
Hypocalcemia 1 0 1 13
Hypophosphatemia 1 0 1 13
Lower extremity edema 1 0 1 13
Weight loss 2 0 0 13
Elevated alkaline phosphatse 0 1 1 13
TOTAL EVENTS 47 23 29
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